Premium
Expression and clinical significance of MAGE and NY‐ESO‐1 cancer‐testis antigens in adenoid cystic carcinoma of the head and neck
Author(s) -
Veit Johannes A.,
Heine Daniela,
Thierauf Julia,
Lennerz Jochen,
Shetty Subasch,
Schuler Patrick J.,
Whiteside Theresa,
Beutner Dirk,
Meyer Moritz,
Grünewald Inga,
Ritter Gerd,
Gnjatic Sacha,
Sikora Andrew G.,
Hoffmann Thomas K.,
Laban Simon
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24403
Subject(s) - adenoid cystic carcinoma , head and neck cancer , medicine , head and neck , antigen , carcinoma , oncology , cancer , cancer research , immunology , surgery
Background Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer‐testis antigens (CTAs) represent an immunogenic family of cancer‐specific proteins and thus represent an attractive target for immunotherapy. Methods Eighty‐four cases of ACC were identified, the CTAs pan‐Melanoma antigen (pan‐MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY‐ESO‐1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. Results Expression of NY‐ESO‐1 was found in 48 of 84 patients (57.1%) and of pan‐MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY‐ESO‐1 positive versus negative patients was 130.8 and 282.0 months ( p = .223), respectively. OS in pan‐MAGE positive versus negative patients was 105.3 and 190.5 months, respectively ( p = .096). Patients expressing both NY‐ESO‐1 and pan‐MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients ( p = .047). Conclusion A significant fraction of patients with ACC show expression of the CTAs NY‐ESO‐1 and/or pan‐MAGE with promising immunotherapeutic implications. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1008–1016, 2016